Here, we have demonstrated that SALL2 increases the Silmitasertib cytotoxicity in SW480 colorectal cancer cells and in AKP-derived organoids, a valid alternative to animal treatment that supports the relevance of the association between CK2 and SALL2. The gene discussed is SALL2; the disease is colorectal cancer.